Compile Data Set for Download or QSAR
Report error Found 422 Enz. Inhib. hit(s) with all data for entry = 11742
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643291(US20240002391, Compound 1)
Affinity DataEC50:  22.4nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643292(US20240002391, Compound 3)
Affinity DataEC50:  1.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643293(US20240002391, Compound 4)
Affinity DataEC50:  1.10nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643294(US20240002391, Compound 6)
Affinity DataEC50:  1.10nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643295(US20240002391, Compound 7)
Affinity DataEC50:  4.60nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643296(US20240002391, Compound 8)
Affinity DataEC50:  0.600nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643297(US20240002391, Compound 9)
Affinity DataEC50:  9.96E+3nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643298(US20240002391, Compound 10)
Affinity DataEC50:  93.8nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643299(US20240002391, Compound 13)
Affinity DataEC50:  5.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643300(US20240002391, Compound 15)
Affinity DataEC50:  33.7nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643301(US20240002391, Compound 16)
Affinity DataEC50:  34.4nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643302(US20240002391, Compound 17)
Affinity DataEC50:  17.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643303(US20240002391, Compound 18)
Affinity DataEC50:  7.40nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643304(US20240002391, Compound 19)
Affinity DataEC50:  14.1nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643305(US20240002391, Compound 20)
Affinity DataEC50:  3.40nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643306(US20240002391, Compound 24)
Affinity DataEC50:  14.3nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643307(US20240002391, Compound 26)
Affinity DataEC50:  7.10nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643308(US20240002391, Compound 27)
Affinity DataEC50:  9.96E+3nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643309(US20240002391, Compound 29)
Affinity DataEC50:  9.20nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643310(US20240002391, Compound 30)
Affinity DataEC50:  22.1nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643311(US20240002391, Compound 31)
Affinity DataEC50:  7.70nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643312(US20240002391, Compound 34)
Affinity DataEC50:  6.20nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643313(US20240002391, Compound 36)
Affinity DataEC50:  12.1nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643314(US20240002391, Compound 37)
Affinity DataEC50:  2.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643315(US20240002391, Compound 39)
Affinity DataEC50:  2.90nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643316(US20240002391, Compound 40)
Affinity DataEC50:  1.60nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643317(US20240002391, Compound 43)
Affinity DataEC50:  1.30nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643318(US20240002391, Compound 44)
Affinity DataEC50:  3.20nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643319(US20240002391, Compound 45)
Affinity DataEC50:  9.30nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643320(US20240002391, Compound 49)
Affinity DataEC50:  2.60nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643321(US20240002391, Compound 51)
Affinity DataEC50:  6.70nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643322(US20240002391, Compound 52)
Affinity DataEC50:  5.20nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643323(US20240002391, Compound 53)
Affinity DataEC50:  0.700nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643324(US20240002391, Compound 54)
Affinity DataEC50:  1.20nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643325(US20240002391, Compound 55)
Affinity DataEC50:  6.70nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643326(US20240002391, Compound 56)
Affinity DataEC50:  1.30nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643327(US20240002391, Compound 61)
Affinity DataEC50:  4.90nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643328(US20240002391, Compound 62)
Affinity DataEC50:  8.5nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643329(US20240002391, Compound 63)
Affinity DataEC50:  4.60nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643330(US20240002391, Compound 67)
Affinity DataEC50:  5.60nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643331(US20240002391, Compound 74)
Affinity DataEC50:  5.20nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643332(US20240002391, Compound 80)
Affinity DataEC50:  56.2nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643333(US20240002391, Compound 91)
Affinity DataEC50:  1.60nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643334(US20240002391, Compound 92)
Affinity DataEC50:  62.6nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643335(US20240002391, Compound 93)
Affinity DataEC50:  194nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643336(US20240002391, Compound 94)
Affinity DataEC50:  4.10nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643337(US20240002391, Compound 95)
Affinity DataEC50:  8.20nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643338(US20240002391, Compound 96)
Affinity DataEC50:  1nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643339(US20240002391, Compound 97)
Affinity DataEC50:  1.10nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Biosplice Therapeutics

US Patent
LigandPNGBDBM643340(US20240002391, Compound 98)
Affinity DataEC50:  25.6nMAssay Description:Briefly, recombinant DYRK1A kinase, ATP and Ser/Thr peptide 18 were prepared in 1X Kinase buffer to final concentrations of 0.25 μg/mL, 15 μ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 422 total ) | Next | Last >>
Jump to: